blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2250256

EP2250256 - OPTIMISATION OF EXPRESSION OF PARVOVIRAL REP AND CAP PROTEINS IN INSECT CELLS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.06.2018
Database last updated on 14.06.2024
FormerThe patent has been granted
Status updated on  30.06.2017
FormerGrant of patent is intended
Status updated on  20.02.2017
FormerExamination is in progress
Status updated on  05.12.2016
Most recent event   Tooltip26.06.2020Lapse of the patent in a contracting state
New state(s): CY, MK		published on 29.07.2020  [2020/31]
Applicant(s)For all designated states
uniQure IP B.V.
Paasheuvelweg 25a
1105 BP Amsterdam / NL
[2017/29]
Former [2014/37]For all designated states
uniQure IP B.V.
Meibergdreef 61
1105 BA Amsterdam / NL
Former [2012/36]For all designated states
UniQure IP B.V.
Meibergdreef 61
1105 BA Amsterdam / NL
Former [2010/46]For all designated states
Amsterdam Molecular Therapeutics (AMT) B.V.
Meibergdreef 61
1105 BA Amsterdam / NL
Inventor(s)01 / BAKKER, Andrew Christian
Leguaanstraat 23
NL-1338 HB Almere / NL
02 / HERMENS, Wilhelmus Theodorus Johannes Maria@Christiaan
Sprietzeil 83
NL-1319 EB Almere / NL
03 / NOORDMAN, Yvet
Prinses Irenelaan 107
NL-3554 HD Utrecht / NL
 [2017/31]
Former [2010/46]01 / BAKKER, Andrew Christian
Leguaanstraat 23
NL-1338 HB Almere / NL
02 / HERMENS, Wilhelmus Theodorus Johannes Maria Christiaan
Sprietzeil 83
NL-1319 EB Almere / NL
03 / NOORDMAN, Yvet
Prinses Irenelaan 107
NL-3554 HD Utrecht / NL
Representative(s)Nederlandsch Octrooibureau
P.O. Box 29720
2502 LS The Hague / NL
[2013/28]
Former [2010/46]Swinkels, Bart Willem
Nederlandsch Octrooibureau J. W. Frisolaan 13
2517 JS Den Haag / NL
Application number, filing date09713345.819.02.2009
[2010/46]
WO2009NL50076
Priority number, dateEP2008015163419.02.2008         Original published format: EP 08151634
US20080029673P19.02.2008         Original published format: US 29673 P
[2017/12]
Former [2010/46]EP2008015163419.02.2008
US2008002967319.02.2008
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009104964
Date:27.08.2009
Language:EN
[2009/35]
Type: A1 Application with search report 
No.:EP2250256
Date:17.11.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 27.08.2009 takes the place of the publication of the European patent application.
[2010/46]
Type: B1 Patent specification 
No.:EP2250256
Date:02.08.2017
Language:EN
[2017/31]
Search report(s)International search report - published on:EP27.08.2009
ClassificationIPC:C12N7/04, C07K14/015, C12N5/10, C12N15/85, C12N15/864
[2017/09]
CPC:
C07K14/005 (EP,US); C12N15/86 (US); C12N7/00 (EP,US);
C12N2710/14143 (EP,US); C12N2750/14122 (EP,US); C12N2750/14243 (EP,US);
C12N2800/105 (EP,US); C12N2800/50 (EP,US) (-)
Former IPC [2010/46]C12N7/04, C07K14/015, C12N5/06, C12N5/10, C12N15/85, C12N15/864
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/31]
Former [2010/46]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL13.09.2010
BA13.09.2010
RS13.09.2010
TitleGerman:OPTIMIERUNG DER EXPRESSION PARVOVIRALER REP UND CAP PROTEINE IN INSEKTENZELLEN[2017/09]
English:OPTIMISATION OF EXPRESSION OF PARVOVIRAL REP AND CAP PROTEINS IN INSECT CELLS[2010/46]
French:OPTIMISATION DE L'EXPRESSION DE PROTÉINES REP ET CAP DE PARVOVIRUS DANS DES CELLULES D'INSECTES[2017/09]
Former [2010/46]OPTIMIERUNG DER EXPRESSION VON REP- UND CAP-PROTEINEN AUS PARVOVIRUS IN INSEKTENZELLEN
Former [2010/46]OPTIMISATION DE L'EXPRESSION DE PROTÉINES REP ET CAP PARVOVIRALES DANS DES CELLULES D'INSECTES
Entry into regional phase13.09.2010National basic fee paid 
13.09.2010Designation fee(s) paid 
13.09.2010Examination fee paid 
Examination procedure13.09.2010Examination requested  [2010/46]
18.01.2011Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
28.03.2011Amendment by applicant (claims and/or description)
07.10.2015Despatch of a communication from the examining division (Time limit: M04)
12.01.2016Reply to a communication from the examining division
03.06.2016Despatch of a communication from the examining division (Time limit: M06)
02.12.2016Reply to a communication from the examining division
21.02.2017Communication of intention to grant the patent
21.06.2017Fee for grant paid
21.06.2017Fee for publishing/printing paid
21.06.2017Receipt of the translation of the claim(s)
Divisional application(s)EP17181630.9  / EP3257937
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  07.10.2015
Opposition(s)03.05.2018No opposition filed within time limit [2018/28]
Request for further processing for:28.03.2011Request for further processing filed
28.03.2011Full payment received (date of receipt of payment)
Request granted
11.04.2011Decision despatched
Fees paidRenewal fee
22.12.2010Renewal fee patent year 03
31.01.2012Renewal fee patent year 04
30.11.2012Renewal fee patent year 05
31.01.2014Renewal fee patent year 06
30.01.2015Renewal fee patent year 07
29.01.2016Renewal fee patent year 08
31.01.2017Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.02.2009
AT02.08.2017
CY02.08.2017
CZ02.08.2017
DK02.08.2017
EE02.08.2017
FI02.08.2017
HR02.08.2017
LT02.08.2017
LV02.08.2017
MC02.08.2017
MK02.08.2017
PL02.08.2017
PT02.08.2017
RO02.08.2017
SE02.08.2017
SI02.08.2017
SK02.08.2017
TR02.08.2017
BG02.11.2017
NO02.11.2017
GR03.11.2017
IS02.12.2017
LU19.02.2018
MT19.02.2018
[2020/31]
Former [2020/27]HU19.02.2009
AT02.08.2017
CZ02.08.2017
DK02.08.2017
EE02.08.2017
FI02.08.2017
HR02.08.2017
LT02.08.2017
LV02.08.2017
MC02.08.2017
PL02.08.2017
PT02.08.2017
RO02.08.2017
SE02.08.2017
SI02.08.2017
SK02.08.2017
TR02.08.2017
BG02.11.2017
NO02.11.2017
GR03.11.2017
IS02.12.2017
LU19.02.2018
MT19.02.2018
Former [2020/15]AT02.08.2017
CZ02.08.2017
DK02.08.2017
EE02.08.2017
FI02.08.2017
HR02.08.2017
LT02.08.2017
LV02.08.2017
MC02.08.2017
PL02.08.2017
RO02.08.2017
SE02.08.2017
SI02.08.2017
SK02.08.2017
TR02.08.2017
BG02.11.2017
NO02.11.2017
GR03.11.2017
IS02.12.2017
LU19.02.2018
MT19.02.2018
Former [2020/08]AT02.08.2017
CZ02.08.2017
DK02.08.2017
EE02.08.2017
FI02.08.2017
HR02.08.2017
LT02.08.2017
LV02.08.2017
MC02.08.2017
PL02.08.2017
RO02.08.2017
SE02.08.2017
SI02.08.2017
SK02.08.2017
BG02.11.2017
NO02.11.2017
GR03.11.2017
IS02.12.2017
LU19.02.2018
MT19.02.2018
Former [2018/52]AT02.08.2017
CZ02.08.2017
DK02.08.2017
EE02.08.2017
FI02.08.2017
HR02.08.2017
LT02.08.2017
LV02.08.2017
MC02.08.2017
PL02.08.2017
RO02.08.2017
SE02.08.2017
SI02.08.2017
SK02.08.2017
BG02.11.2017
NO02.11.2017
GR03.11.2017
IS02.12.2017
LU19.02.2018
Former [2018/44]AT02.08.2017
CZ02.08.2017
DK02.08.2017
EE02.08.2017
FI02.08.2017
HR02.08.2017
LT02.08.2017
LV02.08.2017
MC02.08.2017
PL02.08.2017
RO02.08.2017
SE02.08.2017
SI02.08.2017
SK02.08.2017
BG02.11.2017
NO02.11.2017
GR03.11.2017
IS02.12.2017
Former [2018/39]AT02.08.2017
CZ02.08.2017
DK02.08.2017
EE02.08.2017
FI02.08.2017
HR02.08.2017
LT02.08.2017
LV02.08.2017
PL02.08.2017
RO02.08.2017
SE02.08.2017
SI02.08.2017
SK02.08.2017
BG02.11.2017
NO02.11.2017
GR03.11.2017
IS02.12.2017
Former [2018/23]AT02.08.2017
CZ02.08.2017
DK02.08.2017
EE02.08.2017
FI02.08.2017
HR02.08.2017
LT02.08.2017
LV02.08.2017
PL02.08.2017
RO02.08.2017
SE02.08.2017
SK02.08.2017
BG02.11.2017
NO02.11.2017
GR03.11.2017
IS02.12.2017
Former [2018/21]AT02.08.2017
CZ02.08.2017
DK02.08.2017
FI02.08.2017
HR02.08.2017
LT02.08.2017
LV02.08.2017
PL02.08.2017
SE02.08.2017
BG02.11.2017
NO02.11.2017
GR03.11.2017
IS02.12.2017
Former [2018/12]AT02.08.2017
FI02.08.2017
HR02.08.2017
LT02.08.2017
LV02.08.2017
PL02.08.2017
SE02.08.2017
BG02.11.2017
NO02.11.2017
GR03.11.2017
IS02.12.2017
Former [2018/10]AT02.08.2017
FI02.08.2017
HR02.08.2017
LT02.08.2017
SE02.08.2017
NO02.11.2017
Former [2018/09]FI02.08.2017
LT02.08.2017
SE02.08.2017
NO02.11.2017
Former [2018/08]FI02.08.2017
LT02.08.2017
NO02.11.2017
Former [2018/07]LT02.08.2017
NO02.11.2017
Cited inInternational search[X]US2003148506  (KOTIN ROBERT M [US], et al) [X] 1-8,12-15 * paragraphs [0036] , [0037]; figure 3 *;
 [X]WO2007084773  (ASKLEPIO BIOPHARMACEUTICAL INC [US], et al) [X] 1-8,12-15 * vector Bac-Rep-2.5Cap * * vector Bac-Rep78-2.5Cap *; paragraph [0020]; figures 8-10 *;
 [AD]WO2007148971  (AMSTERDAM MOLECULAR THERAPEUTICS BV [NL], et al) [AD] * the whole document *;
 [PX]WO2008024998  (VIROVEK INC [US], et al) [PX] 1-4,8,12-15 * helper construct Bac-inRep-inCap *;; figures 4,545,46; claim 29 *;
 [A]  - AUCOIN MARC G ET AL, "Production of adeno-associated viral vectors in insect cells using triple infection: optimization of baculovirus concentration ratios", BIOTECHNOLOGY AND BIOENGINEERING 20 DEC 2006,, (20061220), vol. 95, no. 6, pages 1081 - 1092, XP002480825 [A] 1-9 * page 1089, column R, paragraph 2 - page 1090, column R, line L; figure 3 * * page 1091, column R, paragraph L *

DOI:   http://dx.doi.org/10.1002/bit.21069
 [AD]  - URABE M ET AL, "Insect cells as a factory to produce adeno-associated virus type 2 vectors", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, (20021101), vol. 13, no. 16, ISSN 1043-0342, pages 1935 - 1943, XP002394454 [AD] * the whole document *

DOI:   http://dx.doi.org/10.1089/10430340260355347
 [AD]  - KOHLBRENNER ET AL, "Successful Production of Pseudotyped rAAV Vectors Using a Modified Baculovirus Expression System", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, (20051201), vol. 12, no. 6, ISSN 1525-0016, pages 1217 - 1225, XP005176630 [AD] * the whole document *
 [A]  - HUANG KUO-SHIANG ET AL, "Combination of baculovirus-mediated gene delivery and packed-bed reactor for scalable production of adeno-associated virus", HUMAN GENE THERAPY, (200711), vol. 18, no. 11, ISSN 1043-0342, pages 1161 - 1170, XP002486184 [A] 10 * helper baculovirus Bac-RC *;; figure 2A *

DOI:   http://dx.doi.org/10.1089/hum.2007.107
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.